Mackenzie Financial Corp Grows Position in Abbott Laboratories $ABT

Mackenzie Financial Corp grew its position in Abbott Laboratories (NYSE:ABT) by 2.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,507,609 shares of the healthcare product maker’s stock after purchasing an additional 29,440 shares during the quarter. Mackenzie Financial Corp’s holdings in Abbott Laboratories were worth $201,929,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ABT. Franklin Resources Inc. lifted its holdings in Abbott Laboratories by 8.8% during the 3rd quarter. Franklin Resources Inc. now owns 10,303,321 shares of the healthcare product maker’s stock worth $1,379,290,000 after buying an additional 831,746 shares during the last quarter. Magnetar Financial LLC purchased a new position in Abbott Laboratories in the 3rd quarter valued at approximately $2,406,000. Quadrant Capital Group LLC raised its stake in shares of Abbott Laboratories by 0.4% during the 3rd quarter. Quadrant Capital Group LLC now owns 49,192 shares of the healthcare product maker’s stock worth $6,589,000 after buying an additional 183 shares during the last quarter. Van ECK Associates Corp raised its position in Abbott Laboratories by 6.5% during the third quarter. Van ECK Associates Corp now owns 376,449 shares of the healthcare product maker’s stock worth $50,422,000 after acquiring an additional 22,977 shares during the last quarter. Finally, Capital World Investors raised its position in shares of Abbott Laboratories by 0.5% during the 3rd quarter. Capital World Investors now owns 8,927,102 shares of the healthcare product maker’s stock worth $1,195,680,000 after purchasing an additional 43,576 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Activity

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares in the company, valued at $16,918,253.66. This represents a 0.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Eric Shroff sold 709 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the sale, the senior vice president directly owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ABT. Citigroup reduced their target price on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Evercore cut their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Barclays decreased their price target on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a report on Monday, February 2nd. The Goldman Sachs Group lowered their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Finally, Piper Sandler reduced their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $136.37.

Abbott Laboratories Price Performance

ABT stock opened at $110.60 on Wednesday. The firm has a 50-day moving average of $115.55 and a two-hundred day moving average of $124.29. Abbott Laboratories has a one year low of $105.27 and a one year high of $139.06. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $192.18 billion, a PE ratio of 29.73, a P/E/G ratio of 1.79 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.